BioVersys
Clinical-stage Swiss biopharmaceutical company focused on discovery and development of small-molecule therapies to address antimicrobial resistance (AMR). Advances candidates targeting high-priority bacterial pathogens (including carbapenem-resistant Acinetobacter baumannii, Staphylococcus aureus, tuberculosis and nontuberculous mycobacteria) from lead optimization through clinical development, and works with academic, public and industry partners to secure non-dilutive funding and progress programs.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Intravenous reformulated rifamycin candidate for carbapenem-resistant Acinetobacter baumannii
Reformulated intravenous rifamycin-based candidate developed for treatment of carbapenem-resistant A. baumannii lung and bloodstream infections; progressed into clinical development.
Ethionamide potentiator small molecule for MDR-TB and TB meningitis
Small-molecule potentiator that augments and reverts resistance to ethionamide, developed for multidrug-resistant tuberculosis and TB meningitis; progressed in clinical trials.
Anti-virulence small-molecule candidate for Staphylococcus aureus
Small-molecule candidate that reduces toxin production in S. aureus for potential use in skin conditions and as adjunctive therapy for severe infections.
Ribosome-binding broad-spectrum antibacterial series
Chemical series inhibiting a novel ribosomal binding site with coverage across priority pathogens; in preclinical development.
RNA polymerase-targeting research series for nontuberculous mycobacteria (NTM)
Research program focused on RNA polymerase-targeting small molecules intended to address NTM pulmonary infections.
Intravenous reformulated rifamycin candidate for carbapenem-resistant Acinetobacter baumannii
Reformulated intravenous rifamycin-based candidate developed for treatment of carbapenem-resistant A. baumannii lung and bloodstream infections; progressed into clinical development.
Ethionamide potentiator small molecule for MDR-TB and TB meningitis
Small-molecule potentiator that augments and reverts resistance to ethionamide, developed for multidrug-resistant tuberculosis and TB meningitis; progressed in clinical trials.
Anti-virulence small-molecule candidate for Staphylococcus aureus
Small-molecule candidate that reduces toxin production in S. aureus for potential use in skin conditions and as adjunctive therapy for severe infections.
Ribosome-binding broad-spectrum antibacterial series
Chemical series inhibiting a novel ribosomal binding site with coverage across priority pathogens; in preclinical development.
RNA polymerase-targeting research series for nontuberculous mycobacteria (NTM)
Research program focused on RNA polymerase-targeting small molecules intended to address NTM pulmonary infections.
Services
In‑licensing, co-development and out‑licensing of antibacterial development programs with academic and industry partners; management of collaborative funding mechanisms.
Clinical program management, trial operations and quality oversight to support antibacterial candidate development.
In‑licensing, co-development and out‑licensing of antibacterial development programs with academic and industry partners; management of collaborative funding mechanisms.
Clinical program management, trial operations and quality oversight to support antibacterial candidate development.
Expertise Areas
- Antibacterial small-molecule drug discovery
- Transcriptional regulator inhibitor development
- Anti-virulence therapeutic research
- Clinical trial management for anti-infectives
Key Technologies
- Small-molecule medicinal chemistry
- Whole-cell antibacterial screening
- PK/PD modelling
- Nanoparticle drug delivery
News & Updates
Participation and one‑to‑one partnering meetings to discuss clinical pipeline developments and collaboration opportunities.
Attendance at a major conference on antimicrobial resistance and infectious diseases to present pipeline developments and meet stakeholders.
Participation in a European forum on antibiotic policy, R&D innovation and finance to discuss pipeline developments and collaborations.
Digital partnering meetings to discuss clinical pipeline developments and collaboration opportunities.
One‑to‑one investor meeting to discuss company progress and funding opportunities.
Participation at a major healthcare investor conference.
Participation and one‑to‑one partnering meetings to discuss clinical pipeline developments and collaboration opportunities.
Attendance at a major conference on antimicrobial resistance and infectious diseases to present pipeline developments and meet stakeholders.
Participation in a European forum on antibiotic policy, R&D innovation and finance to discuss pipeline developments and collaborations.
Digital partnering meetings to discuss clinical pipeline developments and collaboration opportunities.
One‑to‑one investor meeting to discuss company progress and funding opportunities.
Participation at a major healthcare investor conference.